Livzon Pharmaceutical Group Inc.
000513
Rang in Aktien
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Aktienkurs
$3.90
Marktkapitalisierung
$3.17B
Veränderung (1 Tag)
-3.49%
Veränderung (1 Jahr)
-25.88%
Land
CN
Handel Livzon Pharmaceutical Group Inc. (000513)
Kategorie
Healthcare
Gewinn für Livzon Pharmaceutical Group Inc. (000513)
Gewinn im Jun 2026 TTM: $353.39M
Laut den aktuellen Finanzberichten von Livzon Pharmaceutical Group Inc. betragen die aktuellen Gewinne des Unternehmens $353.39M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $384.45M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $336.60M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Livzon Pharmaceutical Group Inc. von 2001 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $353.39M | -13.61% |
| 2025 | $409.07M | 6.40% |
| 2024 | $384.45M | 14.22% |
| 2023 | $336.60M | -0.37% |
| 2022 | $337.86M | -4.38% |
| 2021 | $353.32M | -7.28% |
| 2020 | $381.07M | 53.60% |
| 2019 | $248.09M | 20.46% |
| 2018 | $205.95M | -76.59% |
| 2017 | $879.92M | 507.84% |
| 2016 | $144.76M | 16.35% |
| 2015 | $124.42M | 18.19% |
| 2014 | $105.27M | 1.52% |
| 2013 | $103.69M | 15.39% |
| 2012 | $89.85M | 22.30% |
| 2011 | $73.47M | -9.13% |
| 2010 | $80.85M | -6.35% |
| 2009 | $86.33M | 457.58% |
| 2008 | $15.48M | -81.76% |
| 2007 | $84.91M | 200.91% |
| 2006 | $28.22M | 72.44% |
| 2005 | $16.36M | -12.46% |
| 2004 | $18.69M | -1.91% |
| 2003 | $19.06M | 40.37% |
| 2002 | $13.58M | 11.75% |
| 2001 | $12.15M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $3.62B | 923.75% |
DE
|
|
| $3.40B | 863.51% |
DE
|
|
| $1.72B | 387.73% |
JP
|
|
| $930.30M | 163.25% |
CH
|
|
| $1.69B | 378.97% |
IN
|
